Angiotensin Converting Enzyme, CSF
Also known as: ACE CSF
Use
The Angiotensin Converting Enzyme test performed on cerebrospinal fluid (CSF) is used to support the diagnosis of neurosarcoidosis. It can also be used to evaluate treatment response in patients suspected of having this condition. Measuring the enzyme levels in CSF can help differentiate neurosarcoidosis from other neurological conditions that may have similar clinical presentations.
Special Instructions
CSF samples containing gadolinium-based contrast agents should not be submitted as they may inhibit ACE activity. Additionally, hemolyzed or xanthochromic specimens are unacceptable for testing.
Limitations
This test is not FDA cleared or approved and it was developed and its performance characteristics determined by ARUP Laboratories. It is performed in a CLIA certified laboratory and intended for clinical purposes. Gadolinium contrast agents can inhibit ACE activity, thus affecting the results. It is crucial to ensure that the CSF sample is free of such agents before submission.
New York Approved
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 12480-0
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP standard transport tube
Causes for Rejection
CSF containing gadolinium-based contrast agents. Hemolyzed or xanthochromic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 hours |
| Refrigerated | 1 week |
| Frozen | 6 months |